Powered by: Motilal Oswal
2026-05-26 10:57:48 am | Source: Religare Broking Ltd
Trade Idea of The Day - Sun Pharmaceutical Industries Ltd Target Rs. 50 - Religare Broking Ltd
Trade Idea of The Day - Sun Pharmaceutical Industries Ltd Target Rs. 50 - Religare Broking Ltd

Sun Pharmaceutical Industries Ltd

BUY 30 JUN 1840 CALL SELL 30 JUN 1900 CALL Entry Range 23 – 25 Target Range 50 Stop Loss 12

Rationale

• On the daily timeframe SUNPHARMA witnessed a healthy pullback after a robust downtick and managed to hold firmly above its 20-DEMA support zone near 1830, indicating the broader bullish undertone remains intact. The prices are continues to trade above its key moving averages, reflecting sustained buying interest at lower levels.

• From the momentum perspective, RSI is hovering near the 60 mark and has reversed upward after cooling off from the overbought zone, suggesting renewed strength and improving price momentum in the near term.

• Additionally, MACD indicator remains in the positive territory despite a minor consolidation phase, while the histogram contraction hints towards a possible fresh bullish crossover in upcoming sessions.

• Overall, the price structure indicates a bullish reversal setup, where any stability above the 1820-1830 zone could trigger renewed buying momentum towards the 1900 and 1950 levels in the short term.

 

Please refer disclaimer at https://www.religareonline.com/disclaimer

SEBI Registration number is INZ00017433

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here